Incannex Healthcare Inc ADR (IXHL) Stock Price, Quote & News

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety diso...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 61 4 0984 0786

Website: www.incannex.com

Address:

8 Century Circuit, Suite 105 Norwest, Sydney, Australia

Michaelthoaicaonguyen Jun. 5 at 1:51 AM

$IXHL brother have a good point and I stated this back in July of 2025. Like I said most of us have done all the due diligence needed before we jump into this company. Again and again I’m telling everyone here, this company is a great company. We have a drug that can and will revolutionize the treatment of OSA. But the only road block we have is management. They keep detouring us to a backward direction instead of forward. Look if this is another Eron, why are the doctors and scientists are still engaged in their work. No doctors have resign or terminated. As bearish as I am to management, I still have faith in our scientists and doctors who are working their asses off. Sadly to say she is at the frontline fighting these battles 1. Management 2. Market opinion (pricing rerate) 3. Short sellers 4. Daily trade off But 2 thru 4 can be control if management knows what they are doing.

0 · Reply

eyeexaechell Jun. 4 at 11:02 PM

$IXHL what's Important to mention also Not effective in treating OSA If you aren't obese? Will never be prescribed for OSA if you're not obese. I literally am in the process right now of doing a sleep study, and aquiring a resmed machine. I'm not big enough to get a GLP-1. So what good is it that it's approved for OSA? If you lose the weight, it stops treating your ailment. OSA only caused by your weight? Well great! You're cured! Otherwise.. it's not an option.

2 · Reply

LazySoo Jun. 4 at 10:02 PM

$IXHL people may have forgot that we have very minimal side effects, compared to these other competitors. But once this second study is done we will be rolling. And before that happens, let’s hope we can see a low float random news real pump. Good luck to all bulls here

1 · Reply

Santa_Claus_Trades Jun. 4 at 9:44 PM

$IXHL No swings for me today. Not enough profit. Need at least 10% to even think about it. Just not worth it to me. That's why my swings are few and far between. I don't flip for pennies. Thanks for the kind words though!

2 · Reply

Michaelthoaicaonguyen Jun. 4 at 9:41 PM

$IXHL buying at $2.99 and selling at $3.26. That’s pretty good @Santa_Claus_Trades. Get your money Mr. Jolly. Absolutely No hate from me. Love you Santa Aaaaaaand back to where we started $3.09. Down 11% since last week, loosing .40. So no more lingering between .11c -.12c. Yall going to hate me for this but our new lingering price will be between .10-.09c. We won’t go any lower than .09c. Thats roughly $2.75 major support zone. Same shit different day

0 · Reply

MikiTrader Jun. 4 at 9:25 PM

$IXHL Zepbound delivers impressive weight loss through dual GLP-1/GIP action, but muscle loss and even hair loss remain concerns. That's likely why Lilly is already studying muscle-preserving combinations like Trevogrumab and Bimagrumab. In the end, the debate won't be "Which drug helps people lose more weight?" but rather "Which drug can keep patients on treatment 5 years from now?" Wegovy and Zepbound still haven't answered that question. As for sleep apnea, Zepbound has a lot of momentum, but I'm not fully convinced yet. This discussion may not be entirely unrelated to IXHL. In a sense, it means that it's not governed by logic.

2 · Reply

ONorABOUT Jun. 4 at 8:53 PM

$IXHL Why does mine say $3.21?

2 · Reply

jackstrawfromwitchita Jun. 4 at 8:50 PM

$IXHL I don't block people here, but OTC Jimmy, wow, if you sold a stock pre RS, why does he keep posting on a stock he doesn't own? I bad mouth the stock myself, but I didn't sell, I've got a right to complain.

3 · Reply

Santa_Claus_Trades Jun. 4 at 8:22 PM

$IXHL Interesting. Stock twits deleted my last three posts. Absolutely nothing that would have violated any TOS. Oh well, C'est la vie!

0 · Reply

macdub8 Jun. 4 at 8:19 PM

$IXHL ended on 0.98% so i wasn't far off Thanks for staying on script.

1 · Reply

Incannex Healthcare Quarterly report: Q3 2026

2026-05-14T19:10:49.000Z - 21 days ago

Incannex commences DReaMzz clinical study of IHL-42X in OSA

May 14, 2026, 10:35 AM EDT - 21 days ago

Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea

May 12, 2026, 8:00 AM EDT - 23 days ago

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

May 7, 2026, 10:00 AM EDT - 4 weeks ago

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

2026-03-27T12:12:54.000Z - 2 months ago

Incannex reactivates share repurchase program

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

2026-03-25T12:11:47.000Z - 2 months ago

Incannex enters partnership agreement with American Academy of Sleep Medicine

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

2026-03-18T12:27:15.000Z - 2 months ago

Incannex reports balance sheet with $75M in cash, no debt

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development

2026-03-17T12:16:04.000Z - 2 months ago

Incannex regains compliance with Nasdaq minimum bid price rule

Mar 17, 2026, 8:00 AM EDT - 2 months ago

Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-03-12T12:27:43.000Z - 3 months ago

Incannex prices 2M shares at $5.00 in registered direct offering

2026-03-12T12:21:15.000Z - 3 months ago

Incannex announces enhanced development strategy for IHL-42X

Mar 12, 2026, 8:05 AM EDT - 3 months ago

Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2026-02-27T00:50:18.000Z - 3 months ago

Incannex Healthcare Inc trading halted, news pending

2026-02-25T14:29:04.000Z - 3 months ago

Incannex board approves 1-for-30 reverse stock split

Feb 25, 2026, 9:20 AM EST - 3 months ago

Incannex Announces Reverse Stock Split

Feb 20, 2026, 6:00 AM EST - 3 months ago

Incannex Healthcare Slides: Investor presentation

Feb 18, 2026, 6:35 PM EST - 3 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026

Feb 13, 2026, 7:00 AM EST - 3 months ago

Incannex Healthcare Quarterly report: Q2 2026

2026-01-29T13:16:52.000Z - 4 months ago

Incannex announces additional appointments to Clinical Advisory Board

Jan 29, 2026, 8:00 AM EST - 4 months ago

Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

2026-01-22T13:21:38.000Z - 4 months ago

Incannex announces formation of clinical advisory board for PSX-001 program

Jan 22, 2026, 8:00 AM EST - 4 months ago

Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program

Jan 15, 2026, 8:00 AM EST - 5 months ago

Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards

2026-01-14T13:05:23.000Z - 5 months ago

Incannex delivers 2025 review, outlines 2026 outlook

Jan 14, 2026, 8:00 AM EST - 5 months ago

Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026

Dec 18, 2025, 7:00 AM EST - 6 months ago

Incannex Healthcare Proxy statement: Proxy Filing

Dec 16, 2025, 7:00 AM EST - 6 months ago

Incannex Healthcare Proxy statement: Proxy Filing

2025-12-03T13:10:21.000Z - 6 months ago

Incannex granted Fast Track designation for IHL-42X in OSA

Dec 3, 2025, 8:00 AM EST - 6 months ago

Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)

Nov 20, 2025, 9:34 AM EST - 7 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026

Nov 14, 2025, 4:00 PM EST - 7 months ago

Incannex Healthcare Quarterly report: Q1 2026

2025-10-30T12:28:51.000Z - 7 months ago

Incannex provides shareholder update including 2025 priorities

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Incannex Healthcare Proxy statement: Proxy Filing

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Incannex Healthcare Proxy statement: Proxy Filing

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Sep 29, 2025, 9:30 AM EDT - 8 months ago

Incannex Healthcare Annual report: Q4 2025

Aug 26, 2025, 8:00 AM EDT - 10 months ago

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

Aug 22, 2025, 8:00 AM EDT - 10 months ago

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

Aug 19, 2025, 4:29 PM EDT - 10 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

Jul 31, 2025, 8:00 AM EDT - 11 months ago

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

Jul 30, 2025, 8:00 AM EDT - 11 months ago

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

Jul 25, 2025, 7:30 AM EDT - 11 months ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

Jun 24, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Jun 18, 2025, 7:30 AM EDT - 1 year ago

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

Jun 17, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jun 3, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

May 29, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

May 28, 2025, 4:21 PM EDT - 1 year ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

May 28, 2025, 7:00 AM EDT - 1 year ago

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

May 20, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

May 16, 2025, 9:00 AM EDT - 1 year ago

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

May 16, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

May 15, 2025, 9:30 AM EDT - 1 year ago

Incannex Healthcare Earnings release: Q3 2025

May 15, 2025, 9:30 AM EDT - 1 year ago

Incannex Healthcare Quarterly report: Q3 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

May 14, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Mar 7, 2025, 2:10 PM EST - 1 year ago

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Feb 18, 2025, 5:51 PM EST - 1 year ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Feb 14, 2025, 7:30 AM EST - 1 year ago

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Feb 14, 2025, 7:00 AM EST - 1 year ago

Incannex Healthcare Earnings release: Q2 2025

Feb 14, 2025, 7:00 AM EST - 1 year ago

Incannex Healthcare Quarterly report: Q2 2025

Feb 4, 2025, 9:15 AM EST - 1 year ago

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Jan 23, 2025, 7:30 AM EST - 1 year ago

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Dec 2, 2024, 4:48 PM EST - 1 year ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Nov 26, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Nov 14, 2024, 4:05 PM EST - 1 year ago

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Nov 14, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Earnings release: Q1 2025

Nov 14, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Quarterly report: Q1 2025

Nov 12, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Oct 2, 2024, 4:50 PM EDT - 1 year ago

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Sep 30, 2024, 4:01 PM EDT - 1 year ago

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

Sep 30, 2024, 6:00 AM EDT - 1 year ago

Incannex Healthcare Earnings release: Q4 2024

Sep 30, 2024, 6:00 AM EDT - 1 year ago

Incannex Healthcare Annual report: Q4 2024

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives

Michaelthoaicaonguyen Jun. 5 at 1:51 AM

0 · Reply

eyeexaechell Jun. 4 at 11:02 PM

2 · Reply

LazySoo Jun. 4 at 10:02 PM

1 · Reply

Santa_Claus_Trades Jun. 4 at 9:44 PM

2 · Reply

Michaelthoaicaonguyen Jun. 4 at 9:41 PM

0 · Reply

MikiTrader Jun. 4 at 9:25 PM

2 · Reply

ONorABOUT Jun. 4 at 8:53 PM

$IXHL Why does mine say $3.21?

2 · Reply

jackstrawfromwitchita Jun. 4 at 8:50 PM

3 · Reply

Santa_Claus_Trades Jun. 4 at 8:22 PM

$IXHL Interesting. Stock twits deleted my last three posts. Absolutely nothing that would have violated any TOS. Oh well, C'est la vie!

0 · Reply

macdub8 Jun. 4 at 8:19 PM

$IXHL ended on 0.98% so i wasn't far off Thanks for staying on script.

1 · Reply

OtCjimmy Jun. 4 at 8:16 PM

$IXHL there are many who've likely saved themselves a lot of losses listening to me and the others filling this board with truth. To those people, I'm glad you've allocated your money elsewhere in the market that is reaching new heights. To those of you who still proudly act stupid and criticize those of us telling the truth. You are morons. I'm sorry but you are. You all advocated for people to buy prior to the OBVIOUS RS. Joel has proven himself a moron countless times but you all believed the next day or the next day he'd suddenly grow a brain 🤣 Good luck to the good ones here. To the others selling lies, be better

1 · Reply

OtCjimmy Jun. 4 at 8:11 PM

$IXHL has no shortage of those who praised Joel and his fake awards. Many have come and gone who analyzed the chart, speculated an NDA, Dubai, or BO would save this. Be careful, folks! Notice the daily volume. Zilch. Nothing. Nada. At 0.50 we hovered for a good two weeks and what happened, the bottom dropped out. Those who've been here have seen up close the idiocy of this board and the apparent denial of the idiot as CEO. He is a tried and true moron. Be careful! Let IXHL show YOU the truth.

1 · Reply

Ea_Nasir Jun. 4 at 8:01 PM

$IXHL wow, another amazing day 🫠

0 · Reply

MikiTrader Jun. 4 at 7:46 PM

$IXHL Looks like someone's been quietly soaking up shares for the past 3 months. Everyone's got their own reasons, I guess. If we assume this is a value play, the fact that it showed any movement at all while everyone was obsessed with space stocks tells me there were still some eyes on it.

0 · Reply

RocketCityRetai1 Jun. 4 at 6:59 PM

$IXHL really tho, I’m not enjoying this.

0 · Reply

RocketCityRetai1 Jun. 4 at 6:59 PM

$IXHL stupid Joel. Instead of going straight to P3 like FDA said you could you do another P2 to optimize dose, streamline P3 and add strength to bargaining position toward any partner or buyer. Smh. Could have dropped P3 news and let retail make our money. Who cares if the FDA asks for a 2nd P3 and the company doesn’t have cash or liquidity to raise cash. Stupid moron Joel

1 · Reply

OtCjimmy Jun. 4 at 5:55 PM

$IXHL almost as if ⬆️ never happened. Joel, you are a moron ⬇️⬇️⬇️🤡🤡🤡

0 · Reply

macdub8 Jun. 4 at 4:21 PM

$IXHL probably the 567th time weve seen this action. Will probably end up 1% or red

2 · Reply

RogueFF7 Jun. 4 at 3:34 PM

$IXHL To be fair since mid March Joel has been executing well with the buybacks and still no ATM. As soon as we get the top line DReAMzz data this will skyrocket imo. It’s why I am here. Australian numbers were blockbuster if they can replicate them. Hopefully it’s why all of us are here. Both Bulls and fatigued investors.

3 · Reply

Michaelthoaicaonguyen Jun. 4 at 3:33 PM

$IXHL this biotech is finally ripping yall. Holding long with Cathy Wood (Ark) and Blackrock investment.

0 · Reply

Michaelthoaicaonguyen Jun. 4 at 3:29 PM

$IXHL all that bashing on Joel and the BoD pays off just a tiny bit. Let’s continue the bashing and see her rise.

0 · Reply

Michaelthoaicaonguyen Jun. 4 at 3:28 PM

$IXHL Santa you don’t need to explain to those who hate the player instead of hating the game. You are still my bull. Do your thing Santa.

1 · Reply

Market Cap	36.61M
Revenue (ttm)	90,000.00
Net Income (ttm)	-46.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52,100.00%
Debt to Equity Ratio	0.00

Volume	135,000
Avg Vol	397,184
Day's Range	N/A - N/A
Shares Out	11.97M
Stochastic %K	13%
Beta	7.00
Analysts	Hold
Price Target	N/A